NCT04063215View on ClinicalTrials.gov

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

October 25, 2024

Study Completion Date

October 25, 2024

Conditions
Traumatic Brain Injury
Interventions
BIOLOGICAL

HB-adMSCs

Hope Biosciences autologous adipose-derived mesenchymal stem cells

Trial Locations (1)

77030

Memorial Hermann Hospital-Clinical Research Unit (MMH-CRU), Houston

Sponsors
All Listed Sponsors
collaborator

The University of Texas Health Science Center, Houston

OTHER

lead

Hope Biosciences LLC

INDUSTRY

NCT04063215 - A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy | Biotech Hunter | Biotech Hunter